Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent
Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
1. A method of treating or preventing an ocular disease in a human subject in need thereof, the method comprising inserting into the canaliculus of the human subject a sustained release biodegradable intracanalicular insert comprising a hydrogel and an active agent, wherein the hydrogel comprises a polymer network comprising polyethylene glycol units having an average molecular weight in the range of from about 2,000 to about 100,000 Daltons, wherein the polymer network comprises multi-arm polymer units comprising 4-8 polyethylene glycol units and cross-linking units comprising fluorescein-conjugated trilysine amide units, wherein the active agent is in the form of particles and wherein the active agent particles are dispersed within the hydrogel.
2. The method of claim 1 , wherein said insert is left to remain in the canaliculus until complete disintegration.
3. The method of claim 1 , wherein the active agent particles have a d50 value of less than about 50 μm.
4. The method of claim 3 , wherein the active agent particles have a d50 value ranging from 3 to 17 μm.
5. The method of claim 1 , wherein the active agent is a low solubility active agent having a solubility in water of less than about 1000 μg/mL.
6. The method of claim 1 , wherein the insert in a dried state contains from about 15% to about 80% by weight of the active agent based on the total weight of the insert and from about 20% to about 60% by weight polymer units based on the total weight of the insert.
7. A method of treating dry eye disease in a subject, the method comprising the steps of:
(a) inserting a first biodegradable insert described in claim 1 into a first canaliculus of a first eye of the subject, wherein the insert comprises:
(1) from about 100 μg to about 800 μg active agent dispersed in the hydrogel;
(2) wherein the active agent releases from the insert over a period of at least about 2-months from the date of inserting the first insert in the subject, at an average rate of about 0.1 μg/day to about 10 μg/day; and
(b) after at least about 2-months from the date of inserting the first insert, inserting a second insert described in claim 1 into the first canaliculus of the first eye in the subject, wherein the second insert is substantially similar to the first insert.
8. The method of claim 7 , wherein the active agent is a low solubility active agent having a solubility in water of less than about 1000 μg/mL.
9. The method of claim 7 , wherein the insert in a dried state contains from about 15% to about 80% by weight of the active agent based on the total weight of the insert and from about 20% to about 60% by weight polymer units based on the total weight of the insert.
10. The method of claim 7 , wherein the insert in a dried state contains from 45% to 55% by weight of the active agent based on the total weight of the insert.
11. The method of claim 7 , wherein the insert contains a surfactant.
12. The method of claim 11 , wherein the insert in a dried state contains from about 0.01% to about 5% by weight of the surfactant based on the total weight of the insert.
13. The method of claim 7 , wherein the amount of impurities as measured by HPLC after at least 3 months, preferably at least 6 of storage at a temperature of from 2 to 8° C. is not more than 3.0%.
14. The method of claim 7 , wherein the active agent is released from the insert after insertion to a human subject at an average rate of about 0.1 μg/day to about 10 μg/day.
15. The method of claim 7 , wherein the tear fluid concentration of active agent after insertion to a human subject ranges from about 0.1 μg/mL to about 10 μg/mL.
16. The method of claim 7 , wherein the insert disintegrates in the canaliculus prior to complete solubilization of the active agent contained in the insert.
17. A method of treating or preventing an ocular disease in a human subject in need thereof, the method comprising inserting into the canaliculus of the human subject a sustained release biodegradable intracanalicular insert comprising a hydrogel and an active agent described in claim 1 , wherein the insert in a dried state contains from about 40% to about 80% by weight of the active agent based on the total weight of the insert.
18. The method of claim 17 , wherein the insert in a dried state contains from 45% to 55% by weight of the active agent based on the total weight of the insert.
19. The method of claim 17 , wherein the insert contains a surfactant.
20. The method of claim 19 , wherein the insert in a dried state contains from about 0.01% to about 5% by weight of a surfactant based on the total weight of the insert.
21. The method of claim 17 , wherein the amount of impurities as measured by HPLC after at least 3 months.
22. The method of claim 17 , wherein the active agent is released from the insert after insertion to a human subject at an average rate of about 0.1 μg/day to about 10 μg/day.
23. The method of claim 17 , wherein the tear fluid concentration of active agent after insertion to a human subject ranges from about 0.1 μg/mL to about 10 μg/mL, and preferably from about 1 μg/mL to about 5 μg/mL.
24. The method of claim 17 , wherein the insert disintegrates in the canaliculus prior to complete solubilization of the active agent particles contained in the insert.
25. The method of claim 7 , wherein the active agent is in the form of particles having a d50 value of less than about 50 μm.
26. The method of claim 25 , wherein the particles have a d50 value ranging from 3 to 17 μm.